Abstract
The management of Basal Cell Carcinoma (BCC) patients (pts) experiencing clinical complete remission (cCR) upon HedgeHog Inhibitors (HHIs) has not been defined yet. We evaluated whether time to HHI stop after cCR is associated to better recurrence-related outcomes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have